Mr. Richard L. Casey This is Me

 View all 15 references Web References

1. 1. cincinnati.bizjournals.com

   cincinnati.bizjournals.com/tri - [Cached]

   Published on: 12/21/2007   Last Visited: 12/24/2007

   CEO Richard Casey hasn't decided yet whether to make a big deal out of Square 1 Bank reaching $1 billion in assets

2. 2. Headlines/Breaking News from Silicon Valley/San Jose Business Journal - bizjournals.com

   sanjose.bizjournals.com/site_m - [Cached]

   Published on: 2/3/2006   Last Visited: 2/3/2006

   Scios Inc. of Mountain View has named Richard Brewer chief executive officer, following the retirement of chairman and CEO Richard Casey.
   ...
   Mr. Casey will stay on as a consultant to Scios for two years.

3. 3. Press Release: 1997: Scios Suspends Development of AURICULIN

   www.gene.com/news/1997/1997040 - [Cached]

   Published on: 4/2/1997   Last Visited: 2/27/2002

   "We are disappointed that the results of this pivotal Phase III clinical trial of AURICULIN in oliguric acute renal failure failed to confirm the positive results we observed in a subgroup of patients in our first Phase III acute renal failure trial," said Richard L. Casey, chairman and chief executive officer. "Despite this development, we remain optimistic about the viability of the other products in our pipeline. Specifically, we still expect to achieve our goal of filing a New Drug Application for NATRECOR® BNP in the first half of 1998. In addition, FIBLAST® trafermin is showing promise in a number of indications. Members of our clinical, regulatory and product development staffs ,who have been involved the development of AURICULIN, will be assigned to either NATRECOR, for acute congestive heart failure, or FIBLAST, for a variety of vascular and neurological disorders."
   
   AURICULIN was under development in collaboration with Genentech, Inc.